Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Suvorexant

The first orexin receptor antagonist approved for insomnia, in the United States in 2014: rather than sedating the brain, it dampens the signal that keeps it awake. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?The name orexin comes from the Greek orexis, appetite: when these neuropeptides were discovered in 1998 they were thought to regulate mainly hunger; only later was their key role in wakefulness understood.

SuvorexantGo to the active ingredient →
SuvorexantActive ingredientSuvorexantCat. No. P-S139-001CAS 1030377-33-3

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.